A large retrospective cohort study indicates HER2-expression is a marker rather than a driver of worse gastric cancer, as it was associated with worse progression-free and overall survival than HER2-negative disease only before adjusting for other long-recognized adverse clinical features. | Karaoğlan, JAMA Netw Open 2026
